Synthesizing Derivatives of 7-Hydroxy-4-{[(5-Methyl-1h- enzimidazol-2-Yl) Sulfanyl] Methyl}-2h-Chromen-2-One and Evaluating Their Potential Anti-Cancer Properties

Abstract

Objective: The research aimed to synthesize novel chromen-2-one derivatives incorporating benzimidazolyl moieties and evaluate their anti-cancer properties.

Experimental: The compounds were synthesized using the Pechmann condensation method. Structural characterization was performed utilizing Fourier-transform infrared spectroscopy (FTIR), proton nuclear magnetic resonance (1H-NMR), and mass spectrometry (MS). The anti-cancer potential of the synthesized derivatives was assessed using the Trypan Blue assay on MCF cell lines.

Results: Several of the synthesized benzimidazolyl chromen-2-one derivatives demonstrated significant anti-cancer activity. The structural characterization confirmed the successful incorporation of benzimidazolyl moieties into the chromen-2-one framework.

Discussion: The promising anti-cancer activities observed in several derivatives suggest their potential as lead compounds for further development in anti-cancer drug research. The use of the Pechmann condensation method proved effective in synthesizing diverse chromen-2-one derivatives with therapeutic potential.

Conclusion: This study successfully synthesized and characterized novel benzimidazolyl chromen-2-one derivatives with noteworthy anti-cancer properties, validating their potential for future anti-cancer drug development. The methodology employed provides a valuable approach for the diversification of chromen-2-one derivatives with potential therapeutic applications.